Show simple item record

dc.contributor.authorBrigden, G*
dc.contributor.authorNyang'wa, B-T*
dc.contributor.authordu Cros, P*
dc.contributor.authorVaraine, F*
dc.contributor.authorHughes, J*
dc.contributor.authorRich, M*
dc.contributor.authorHorsburgh, C R*
dc.contributor.authorMitnick, C D*
dc.contributor.authorNuermberger, E*
dc.contributor.authorMcIlleron, H*
dc.contributor.authorPhillips, Patrick P J*
dc.contributor.authorBalasegaram, M*
dc.date.accessioned2014-01-20T22:08:17Z
dc.date.available2014-01-20T22:08:17Z
dc.date.issued2014-01-01
dc.identifier.citationPrinciples for designing future regimens for multidrug-resistant tuberculosis. 2014, 92 (1):68-74 Bull. World Health Organ.en_GB
dc.identifier.issn1564-0604
dc.identifier.pmid24391302
dc.identifier.doi10.2471/BLT.13.122028
dc.identifier.urihttp://hdl.handle.net/10144/311647
dc.description.abstractFewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex, ineffective, poorly tolerated and expensive. For the first time in over 50 years, new drugs have been developed specifically to treat tuberculosis, with bedaquiline and potentially delamanid expected to be available soon for treatment of MDR cases. However, if the new drugs are merely added to the current treatment regimen, the new regimen will be at least as lengthy, cumbersome and toxic as the existing one. There is an urgent need for strategy and evidence on how to maximize the potential of the new drugs to improve outcomes and shorten treatment. We devised eight key principles for designing future treatment regimens to ensure that, once they are proven safe in clinical trials, they will be clinically effective and programmatically practicable. Regimens should contain at least one new class of drug; be broadly applicable for use against MDR and extensively drug-resistant Mycobacterium tuberculosis complex strains; contain three to five effective drugs, each from a different drug class; be delivered orally; have a simple dosing schedule; have a good side-effect profile that allows limited monitoring; last a maximum of 6 months; and have minimal interaction with antiretrovirals. Following these principles will maximize the potential of new compounds and help to overcome the clinical and programmatic disadvantages and scale-up constraints that plague the current regimen.
dc.language.isoenen
dc.publisherWorld Health Organizationen_GB
dc.rightsArchived with thanks to Bulletin of the World Health Organizationen_GB
dc.subjectTuberculosisen_GB
dc.subjectAntibiotic Resistanceen_GB
dc.titlePrinciples for designing future regimens for multidrug-resistant tuberculosisen
dc.identifier.journalBulletin of the World Health Organizationen_GB
refterms.dateFOA2019-03-04T11:03:14Z
html.description.abstractFewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex, ineffective, poorly tolerated and expensive. For the first time in over 50 years, new drugs have been developed specifically to treat tuberculosis, with bedaquiline and potentially delamanid expected to be available soon for treatment of MDR cases. However, if the new drugs are merely added to the current treatment regimen, the new regimen will be at least as lengthy, cumbersome and toxic as the existing one. There is an urgent need for strategy and evidence on how to maximize the potential of the new drugs to improve outcomes and shorten treatment. We devised eight key principles for designing future treatment regimens to ensure that, once they are proven safe in clinical trials, they will be clinically effective and programmatically practicable. Regimens should contain at least one new class of drug; be broadly applicable for use against MDR and extensively drug-resistant Mycobacterium tuberculosis complex strains; contain three to five effective drugs, each from a different drug class; be delivered orally; have a simple dosing schedule; have a good side-effect profile that allows limited monitoring; last a maximum of 6 months; and have minimal interaction with antiretrovirals. Following these principles will maximize the potential of new compounds and help to overcome the clinical and programmatic disadvantages and scale-up constraints that plague the current regimen.


Files in this item

Thumbnail
Name:
Brigden et al-2013-Principles ...
Size:
801.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record